Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126728912 | 12672891 | 2 | F | 2016 | 20160825 | 20160822 | 20160908 | EXP | JP-VIFOR (INTERNATIONAL) INC.-VIT-2016-04407 | VIFOR | 73.58 | YR | M | Y | 51.00000 | KG | 20160908 | MD | JP | JP |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126728912 | 12672891 | 1 | PS | MIRCERA | METHOXY POLYETHYLENE GLYCOL-EPOETIN BETA | 1 | Intravenous (not otherwise specified) | DOSAGE UNCERTAIN | Y | 0 | |||||||||
| 126728912 | 12672891 | 2 | SS | MIRCERA | METHOXY POLYETHYLENE GLYCOL-EPOETIN BETA | 1 | Intravenous (not otherwise specified) | Y | 0 | 100 | UG | ||||||||
| 126728912 | 12672891 | 3 | SS | MIRCERA | METHOXY POLYETHYLENE GLYCOL-EPOETIN BETA | 1 | Intravenous (not otherwise specified) | Y | 0 | 100 | UG | ||||||||
| 126728912 | 12672891 | 4 | SS | Feburic | FEBUXOSTAT | 1 | Oral | Y | 0 | ||||||||||
| 126728912 | 12672891 | 5 | SS | ADALAT | NIFEDIPINE | 1 | Oral | Y | 0 | ||||||||||
| 126728912 | 12672891 | 6 | SS | Kalimate | CALCIUM POLYSTYRENE SULFONATE | 1 | Oral | DOSAGE IS UNCERTAIN | Y | 0 | |||||||||
| 126728912 | 12672891 | 7 | SS | Mevalotin | PRAVASTATIN SODIUM | 1 | Oral | 1) FRACTIONATION DOSE UNCERTAIN FREQUENCY AND DOSE INTERVAL UNCERTAINTY | Y | 0 | |||||||||
| 126728912 | 12672891 | 8 | SS | Alositol | ALLOPURINOL | 1 | Oral | 0 | |||||||||||
| 126728912 | 12672891 | 9 | C | LASIX | FUROSEMIDE | 1 | Oral | 0 | 20 | MG | |||||||||
| 126728912 | 12672891 | 10 | C | Argamate | CALCIUM POLYSTYRENE SULFONATE | 1 | Oral | 0 |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 126728912 | 12672891 | 1 | Nephrogenic anaemia |
| 126728912 | 12672891 | 4 | Hyperuricaemia |
| 126728912 | 12672891 | 5 | Hypertension |
| 126728912 | 12672891 | 6 | Hyperkalaemia |
| 126728912 | 12672891 | 7 | Hyperlipidaemia |
| 126728912 | 12672891 | 8 | Hyperuricaemia |
| 126728912 | 12672891 | 9 | Hypertension |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 126728912 | 12672891 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 126728912 | 12672891 | Condition aggravated | |
| 126728912 | 12672891 | Drug eruption | |
| 126728912 | 12672891 | Eczema | |
| 126728912 | 12672891 | Eosinophilia | |
| 126728912 | 12672891 | Erythema | |
| 126728912 | 12672891 | Pruritus generalised | |
| 126728912 | 12672891 | Rash |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 126728912 | 12672891 | 1 | 201512 | 201512 | 0 | |
| 126728912 | 12672891 | 2 | 20160324 | 20160324 | 0 | |
| 126728912 | 12672891 | 3 | 20160426 | 20160426 | 0 | |
| 126728912 | 12672891 | 4 | 201512 | 20160427 | 0 | |
| 126728912 | 12672891 | 5 | 201512 | 20160427 | 0 | |
| 126728912 | 12672891 | 6 | 201512 | 20160324 | 0 | |
| 126728912 | 12672891 | 7 | 201512 | 20160427 | 0 | |
| 126728912 | 12672891 | 8 | 20160428 | 20160725 | 0 | |
| 126728912 | 12672891 | 9 | 20160423 | 0 | ||
| 126728912 | 12672891 | 10 | 20160324 | 20160427 | 0 |